• 1
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29:198206.
  • 2
    Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25:735739.
  • 3
    Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype. J Hepatol 2000; 33:106115.
  • 4
    Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy. Hepatology 2002; 36:12661272.
  • 5
    Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34:428434.
  • 6
    Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:13581364.
  • 7
    Gerber MA, Krawczynski K, Alter MJ, Sampliner RE, Margolis HS. Histopathology of community acquired chronic hepatitis C. Mod Pathol 1992; 5:483486.
  • 8
    Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC Jr, Balart LA, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. Gastroenterology 1993; 104:595603.
  • 9
    Bach N, Thung SN, Schaffner R. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15:572577.
  • 10
    Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, Negro F. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001; 39:119124.
  • 11
    Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36:729736.
  • 12
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. PEG-Interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001; 358:958965.
  • 13
    The METAVIR Cooperative Group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20:1520.
  • 14
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289293.
  • 15
    Tong MJ, Hwang SJ, Lefkowitz M, Lee SD, Co RL, Conrad A, Schmid P, et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994; 9:587591.
  • 16
    Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32:654659.
  • 17
    Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterisation of new subtypes using a line probe assay. J Gen Virol 1993; 74:10931102.
  • 18
    Hintze JL. NCSS 97 User Guide. Number Cruncher Statistical Systems. Kaysville, UT, 1997.
  • 19
    Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura T, Eder G, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997; 94:12001205.
  • 20
    Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, Doskeland B, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37:226232.
  • 21
    Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, Saitoh S, et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 2002; 37:831836.
  • 22
    Lewis JA, Huq A, Najarro P. Inhibition of mitochondrial function by interferon. J Biol Chem 1996; 22:1318413190.
  • 23
    Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxydation. J Hepatol 1997; 26:1322.